albuterol and Bruise
albuterol has been researched along with Bruise in 2 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "1465 patients with COPD were recruited from outpatient departments in 25 countries." | 2.71 | Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. ( Anderson, J; Calverley, P; Gulsvik, A; Jones, P; Maden, C; Pauwels, R; Pride, N; Vestbo, J, 2003) |
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Calverley, P | 1 |
| Pauwels, R | 1 |
| Vestbo, J | 2 |
| Jones, P | 1 |
| Pride, N | 1 |
| Gulsvik, A | 1 |
| Anderson, J | 1 |
| Maden, C | 1 |
Clinical Trials (2)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 4 Withdrawal of Inhaled Corticosteroids in Patients With Chronic Obstructive Pulmonary Disease in Primary Care: a Randomised Controlled Trial[NCT00440687] | Phase 4 | 256 participants | Interventional | 2001-01-31 | Completed | ||
| GR Activity in Induced Sputum Macrophages, and a Change in Inflammatory Biomarkers 2-hours After a Single Dose of Either Symbicort®/Budesonide/Formoterol or in Chronic Obstructive Pulmonary Disease (COPD)[NCT01787097] | Phase 4 | 31 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Changes in CXCL8 Levels
Changes in CXCL8 concentrations in sputum compared to screening visit. (NCT01787097)
Timeframe: Screening visit and 2 hours post inhalation of treatment
| Intervention | ng/mL (Mean) |
|---|---|
| Formoterol (FORM) Total Dose 24ug | -0.04 |
| Symbicort® Total Dose 400ug/12ug | -2.1 |
| Symbicort® Total Dose 800ug/24ug | -2.2 |
| Pulmicort 800 | -1.5 |
Changes in IL-6 Levels
Changes in IL-6 Levels in the sputum supernatant compared to screening visit (NCT01787097)
Timeframe: Screening visit and 2 hours post inhalation of treatment
| Intervention | pg/mL (Mean) |
|---|---|
| Formoterol (FORM) Total Dose 24ug | -29 |
| Symbicort® Total Dose 400ug/12ug | -14 |
| Symbicort® Total Dose 800ug/24ug | -28 |
| Pulmicort 800 | -29 |
Changes in Lung Function Parameter FEV1
Improvement in FEV1 compared to baseline levels. (NCT01787097)
Timeframe: Baseline and 2 hours post inhalation
| Intervention | mL (Mean) |
|---|---|
| Formoterol (FORM) Total Dose 24ug | 160 |
| Symbicort® Total Dose 400ug/12ug | 120 |
| Symbicort® Total Dose 800ug/24ug: | 200 |
| Pulmicort 800ug | 52 |
Changes in TNF Alpha
Sputum TNF-alpha levels obtained from induced sputum compared to screening visit. (NCT01787097)
Timeframe: Screening visit and 2 hours post inhalation of treatment
| Intervention | pg/mL (Mean) |
|---|---|
| Formoterol (FORM) Total Dose 24ug | -4.8 |
| Symbicort® Total Dose 400ug/12ug | -5.7 |
| Symbicort® Total Dose 800ug/24ug | -7.8 |
| Pulmicort 800ug | -9.4 |
GR-GRE Binding (Relative to Baseline)
Enzyme immunosorbent assay system (NCT01787097)
Timeframe: Screening visit and 2 hours post inhalation of treatment
| Intervention | Fold activation (Mean) |
|---|---|
| Formoterol (FORM) Total Dose 24ug | 1.1 |
| Symbicort® Total Dose 400ug/12ug | 1.8 |
| Symbicort® Total Dose 800ug/24ug | 2.3 |
| Pulmicort 800ug | 2.1 |
Trials
2 trials available for albuterol and Bruise
| Article | Year |
|---|---|
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
Topics: Adrenergic beta-Agonists; Aged; Albuterol; Androstadienes; Anti-Inflammatory Agents; Contusions; Dou | 2003 |
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
Topics: Adrenergic beta-Agonists; Aged; Albuterol; Androstadienes; Anti-Inflammatory Agents; Contusions; Dou | 2003 |
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
Topics: Adrenergic beta-Agonists; Aged; Albuterol; Androstadienes; Anti-Inflammatory Agents; Contusions; Dou | 2003 |
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
Topics: Adrenergic beta-Agonists; Aged; Albuterol; Androstadienes; Anti-Inflammatory Agents; Contusions; Dou | 2003 |
[Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease].
Topics: Adrenergic beta-Agonists; Aged; Albuterol; Androstadienes; Anti-Inflammatory Agents; Contusions; Dou | 2004 |